CBT (cannabitriol) is a rare, minor cannabinoid found in certain Cannabis sativa L. cultivars, and it's often associated with high-CBD strains, sometimes sourced from "industrial hemp." Understanding the nuances of both CBT and CBD is crucial.
Cannabitriol (CBT): A Rare Cannabinoid
- Discovery: CBT was first discovered in 1966.
- Rarity: It's considered a minor cannabinoid, meaning it's present in relatively small quantities compared to major cannabinoids like THC and CBD.
- Source: While present in various cannabis strains, it's most often found (and therefore more easily sourced) in high-CBD strains, including those classified as "industrial hemp."
- Limited Research: Due to its rarity, research into the effects and potential benefits of CBT is still limited.
Cannabidiol (CBD): The Well-Known Cannabinoid
- Abundance: CBD is one of the most abundant cannabinoids found in cannabis plants.
- Non-Psychoactive: Unlike THC, CBD is non-psychoactive, meaning it doesn't produce a "high."
- Widespread Use: CBD is widely used and studied for potential therapeutic benefits.
- Legality: CBD derived from hemp (containing less than 0.3% THC) is federally legal in the United States.
Relationship Between CBT and CBD
The connection between CBT and CBD is primarily one of co-occurrence. High-CBD cannabis strains are often a source of CBT. This doesn't imply that CBT is a derivative of CBD or vice-versa, but rather that the genetics of certain cannabis plants favor the production of both cannabinoids.
In essence, CBT is a rare companion cannabinoid sometimes found alongside the more prevalent CBD. Further research is needed to fully understand the potential benefits and interactions of CBT.
